Collegium Pharmaceutical Hits New 52-Week High at $43.06

Collegium Pharmaceutical, Inc. has reached a significant milestone by hitting a new 52-week high of USD 43.06 on November 7, 2025. This achievement highlights the company's strong performance within the pharmaceuticals and biotechnology sector, where it operates as a small-cap entity with a market capitalization of USD 1,222 million.
The stock's price performance reflects a notable increase from its 52-week low of USD 23.23, showcasing a substantial upward trend. Collegium's price-to-earnings (P/E) ratio stands at 15.00, indicating a competitive valuation relative to its earnings. Additionally, the company maintains a return on equity of 23.11%, suggesting effective management and profitability.

Despite having a debt-to-equity ratio of 3.04, which indicates a higher reliance on debt financing, Collegium has not offered dividends, as evidenced by a dividend yield of 0.00%. The price-to-book ratio of 5.26 further illustrates the market's valuation of the company's assets. Overall, Collegium Pharmaceutical's recent performance underscores its position in the market and reflects the dynamics of the pharmaceuticals and biotechnology industry.